Figure 5: SRSF10 is required for tumorigenesis of colon cancer cells.

(a) RKO cells were infected with sh-SRSF10 retrovirus and selected for puromyocin resistance. Cell proliferation assay was performed with RKO cells stably expressing sh-SRSF10 along with RKO cells stably expressing sh-BCLAF1-L (1 and 2) for comparison, as described in Fig. 2b. (b,c) Clonogenic survival assays and qualification of RKO or HCT116 cells stably expressing sh-SRSF10 or sh-Luci were performed, as described in Fig. 2c,d. For comparison, cells stably expressing sh-BCLAF1-L (1 or 2) were also included. Three independent experiments were performed and results are shown as mean±s.d. (d) RKO cells were infected with control or shSRSF10 adenovirus. Twelve hours post infection, the cells were transplanted to nude mice, as described in Fig. 3c. After 7 weeks, all the tumours derived from RKO/shSRSF10 or RKO/shLuci cells were shown (top) and tumour weight was measured (bottom), as described in Fig. 3d. Results are shown as mean±s.d. of tumour weights (n=11 and 3, respectively, both with initial 12 injections). (e) Tumours shown in d were formalin-fixed, paraffin-embedded and sliced for Ki67 staining and TUNEL assay, as described in Fig. 3e.